1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA SBIR and STTR Omnibus Solicitation is sponsored by National Institute on Drug Abuse (NIDA) - NIH. NIDA participates in the SBIR and STTR omnibus solicitation to help companies develop innovative ideas that have the potential for technology commercialization and impact on public health, specifically related to substance use disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses, particularly those with a focus on biomedical product development for substance use disorders. Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, unless the proposal falls under approved topics. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NIDA SBIR and STTR Omnibus Solicitation are due April 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIDA SBIR and STTR Omnibus Solicitation is funded by National Institute on Drug Abuse (NIDA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 Clinical Trial Optional) is a grant from the National Institute on Drug Abuse (NIDA) at NIH that funds small business concerns to develop science-based technologies add…
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. This SBIR program aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat Substance Use Disorders (SUDs).
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Institute on Drug Abuse (NIDA) - NIH. NIDA's SBIR/STTR programs support research and development of innovative medical and non-medical products and services for substance use disorders (SUDs) and adverse health consequences related to non-disordered drug use, including AI applications.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNOT-OD-26-120 moved the DMS Plan elimination for NIH Career Development awards from October 12, 2027 to effective immediately. Active, pending, and future K applicants are all covered. Here is what changed, what did not, and where the paperwork will lag the policy.
Read articleNIH is carrying its emergency peer review modifications into the January 2027 Advisory Council with more than 35,000 applications in the queue. Discussion drops to 30-35 percent, the middle third becomes "competitive but not discussed" and stays eligible for funding, and the resume of discussion disappears from your summary statement. Here is what each change does to a real application.
Read article